Morningstar

EU Seeks Views on Sanofi's Concessions to End Competition Probe

Provided by Dow Jones

By Edith Hancock 




  The European Commission is seeking feedback on a package of concessions healthcare group Sanofi offered to end a competition investigation into the company. 



  It comes after the European Union's executive arm started investigating Sanofi in June over concerns it unfairly pursued a campaign to disparage a rival flu vaccine by portraying it as inferior to its own Efluelda. 



  The commission said that Sanofi offered to publish statements on its French and German websites acknowledging assessments of the vaccines carried out by the European Centre for Disease Prevention and Control and national immunisation technical advisory groups, and to avoid portraying rival CSL Seqirus's drug Fluad negatively, or claiming that Efluelda is safer or more effective. 



  The regulator set an Aug. 21 deadline to receive feedback on the offer. 





  Write to Edith Hancock at edith.hancock@wsj.com 





  (END) Dow Jones Newswires



  July 08, 2026 06:11 ET (10:11 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
33 Undervalued Stocks to Buy Before the Market Catches On
 
Here’s the new list of Morningstar’s top analyst picks for the third quarter of 2026. 
 
 
Susan Dziubinski 
 
 
 
3 Great ETFs for Rebalancing Your Portfolio in 2026
 
Consider these options to recenter your portfolio. 
 
 
Zachary Evens 
 
 
 
2 Cheap Stocks to Buy in July
 
The stocks of these wide-moat companies look like bargains today. 
 
 
Susan Dziubinski 
 
 
 
What Investors Should Watch for in the Second Half of 2026
 
Plus, where to look for opportunities in fixed-income and more. 
 
 
Dominic Pappalardo and Ivanna Hampton 
 
 
 
These Simple Portfolio Checks Could Save You From Costly Mistakes
 
Follow these seven steps to keep your financial goals on track in the second half of 2026. 
 
 
Christine Benz 
 
 
 

			Sponsor Center